PharmAbcine Closes USD $6 Million Series A... ( DAEJEON South Korea Sept....)

PharmAbcine Closes USD $6 Million Series A Financing

Date:9/16/2009

DAEJEON, South Korea, Sept. 16 /PRNewswire/ -- PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.

The financing will be primarily used to continue developing a pipeline of fully human therapeutic antibodies in the area of cancer and inflammation. In 2008, PharmAbcine was selected as the winner of business plan competition under 'GATE (Get Armed To Explore Global Market)' project. GATE was a collaborative initiative among the Korea Health Industry Development Institute (KHIDI), Samsung Advanced Institute of Technology (SAIT), McKinsey & Co., the Korea Trade-Investment Promotion Agency (KOTRA), and Novartis.

"We are very excited to make the first investment by OrbiMed in a Korean company and believe that PharmAbcine is uniquely positioned with talented scientists, excellent science and meaningful product opportunities," said Dr. Nancy Chang, Chairman and Senior Managing Director of OrbiMed's Caduceus Asia Partners. "The company's Series A financing is a first where a Korean start-up was able to attract an international syndicate of quality investors. We believe that this experienced syndicate can work well and we look forward to working closely with Novartis, Green Cross, Tong Yang, and Saehan Venture Fund to build PharmAbcine into a first rate biotech company in Korea."

"Novartis Korea Venture Fund puts priority on investing in the best life science start-ups in Korea - our mission is to support Korea as it builds a world class biotech industry," said Dr. Anja Koenig, Managing Director, Novart
'/>"/>

SOURCE PharmAbcine
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. WaferGen Closes on Private Financings of Approx. $6.2 Million
2. Helix BioPharma Closes Private Placement
3. Alimera Sciences Closes $5 Million in Extended Series C Financing
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Micromet Closes $80.5 Million Public Offering of Common Stock
6. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
7. Signostics Closes Follow-On Financing of US$4 Million, Expands Board of Directors
8. NewLink Genetics Corporation Closes $7.5 Million Financing
9. Pharmaxis Closes Share Purchase Plan
10. China Biologic Products Closes the $9.6 Million Private Placement
11. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

Post Your Comments:

(Date:2/9/2010)... endpoint Clinical ( www.endpointclinical.com ), a ... (IWR) systems, announced today that PULSE, a fully ... deploy clinical trial Integrated Response Technology (IRT) systems, ... clinical trials. This time and cost savings stems ... developers do not have to spend valuable time ...

(Date:2/9/2010)... A leading clinical research center in ... study an investigational drug designed as a possible treatment ... affects between 45 and 90 percent of women of ... not life threatening, dysmenorrhea can be debilitating and psychologically ... absenteeism from work and school. ,, Current therapies for ...

(Date:2/9/2010)... BEACH, California and AMSTERDAM , ... in molecular cancer diagnostics, announced today that,it has ... New York State ,Department of Health. The ... to receive,commercial samples of MammaPrint, its FDA-cleared breast ... this latest permit, Agendia has now obtained all ...

(Date:2/9/2010)... February 9 ,, ... Microplasmin to Improve the Treatment,of a Range of ... ThromboGenics NV (Euronext Brussels: THR), a ... innovative treatments for eye,disease, vascular disease and cancer, ... results, evaluating the product,s efficacy and,safety in patients ...

Breaking Biology Technology:endpoint Saves Money and Time for Medical Research Teams Through PULSE 2 endpoint Saves Money and Time for Medical Research Teams Through PULSE 3 Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps 2 Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists 2 ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 2 ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 3 ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 4

[0] endpoint Saves Money and Time for Medical Research Teams Through PULSE [0] Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps [0] Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists [0] ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology

... Training Center Scheduled to Open Friday, Feb. 29, ... Institute, LLC,will open its first training center in the ... local communities. Located in,Milipitas, CA, the center will be ... than 20 million Americans and costs the economy,$174 billion ...

... Continued year over year growth driven by Loestrin 24 ... Warner Chilcott,Limited (Nasdaq: WCRX ) today announced ... 2007. Revenue in the quarter ended December 31, 2007,totaled ... year quarter.,Revenue for the year ended December 31, 2007 ...

... today announced the submission of a supplemental New ... Administration (FDA) for once- daily,SEROQUEL XR(TM) (quetiapine fumarate) ... major depressive disorder (MDD) as,monotherapy, adjunct therapy, and ... 15 million American adults -- between 5 and ...

MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder

(Date:2/9/2010)... Miami have analyzed images based on Synthetic Aperture ... Haiti,s earthquake, on January 12. The images reveal ... using data from Japan,s ALOS satellite and made ... of the European Space Agency (ESA) and GEO, ... of countries that promotes the exchange of satellite ...

(Date:2/9/2010)... People with anorexia nervosa, paradoxically, have strikingly high levels ... Children,s Hospital Boston. Their findings, based on MRI imaging ... 20 healthy girls of the same age, appear in ... and Mineral Research . , "It,s counter-intuitive that an ... be storing fat in her marrow," says endocrinologist Catherine ...

(Date:2/9/2010)... The Scripps Research Institute have discovered a potential new ... for sheep and cattle infected with liver fluke. The ... in combating river blindness, a tropical disease that is ... humans. , The study is scheduled for publication ... Proceedings of the National Academy of Sciences ...

Breaking Biology News(10 mins):New international satellite observations help assess future earthquake risk in Haiti 2 Anorexics found to have excess fat-- in their bone marrow 2 Scripps research team reveals how an old drug could have a new use for treating river blindness 2 Scripps research team reveals how an old drug could have a new use for treating river blindness 3 Scripps research team reveals how an old drug could have a new use for treating river blindness 4 GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 1 GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 2 GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 3 GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 4 New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 1 New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 2 New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 3 New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 4 Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 1 Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 2

[0] New international satellite observations help assess future earthquake risk in Haiti [0] Anorexics found to have excess fat-- in their bone marrow [0] Scripps research team reveals how an old drug could have a new use for treating river blindness

... prevent global warming, researchers and policymakers are exploring a ... carbon dioxide that reaches the atmosphere. One possible approach ... the source an electric power plant, for example ... theoretically promising, the technique has never been tested in ...

... or array that can quickly detect disorders such as Down ... effective tool in prenatal diagnosis in a series of 300 ... report that appears in the current issue of the journal ... led by Dr. Arthur Beaudet and Dr. Sau Wai Cheung ...

... properties of cancer cells are their ability to divide without ... establish new tumor sites. Now, researchers from the Mayo ... acts as a deadly master switch, both freeing cancer cells ... is potentially good news, say the researchers, who published their ...

Other Biology News:MIT: Safe storage of greenhouse-gas carbon dioxide 2 Microarray analysis improves prenatal diagnosis 2 Microarray analysis improves prenatal diagnosis 3 Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth 2 Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth 3

MIT: Safe storage of greenhouse-gas carbon dioxide Microarray analysis improves prenatal diagnosis Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth

Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....

Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...

Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...

Request Info...

Biology Products:

Mouse Anti-Cig2 Monoclonal Antibody, Unconjugated, Clone CIG 3A11 / 5 from Abcam Mouse Anti-Myosin, heavy chain I, smooth muscle Monoclonal Antibody, Unconjugated, Clone 3F8 from Abcam Rabbit Anti-CAMK 1D beta Polyclonal Antibody, Unconjugated from Abcam Anti-Neurotensin Receptor Monoclonal Antibody, Unconjugated , Clone B-N6 from Cell Sciences

PharmAbcine Closes USD $6 Million Series A...( DAEJEON South Korea Sept....)